Core Insights - Edwards Lifesciences Corporation (NYSE:EW) is recognized as one of the top medical device stocks to invest in, with Piper Sandler maintaining an Overweight rating and a $90 price target ahead of the PARTNER 3 study findings [1][2] Group 1: Company Overview - Edwards Lifesciences Corporation specializes in developing and selling patient-focused medical innovations, including transcatheter heart valves and hemodynamic monitoring systems for treating structural heart disease and critical care [2] Group 2: PARTNER 3 Study - The PARTNER 3 trial, which has a follow-up period of ten years, compares surgical aortic valve replacement (SAVR) with the Sapien 3 transcatheter aortic valve replacement (TAVR) in low-risk patients [2] - Upcoming data from the PARTNER 3 study is expected to demonstrate that TAVR is not inferior to SAVR, which may result in findings that have minimal commercial implications [2]